Evidence map›Paper›PMID 33408914›Full record

ArticleSurgical neurology international2020

Mesenchymal stem cells in Parkinson's disease: Motor and nonmotor symptoms in the early posttransplant period.

Aliaksandr Boika, Natallia Aleinikava, Veranika Chyzhyk, Marina Zafranskaya, Darya Nizheharodava, Vladimir Ponomarev

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical neurology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04146519 (Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology), which is not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04146519 phase2 / phase3unknown statusnot on this map

Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology

TypeinterventionalSponsorBelarusian Medical Academy of Post-Graduate EducationRan2017 to 2021Enrolled50ConditionsTransplantation:Mesenchymal Stem Cell TransplantationArmsAutologous mesenchymal stem cells, Placebo
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.Movement disorders : official journal of the Movement Disorder Society · 2025
    Trial
  6. Review
  7. Review
  8. Article
  9. Nose-to-brain drug delivery: from bench to bedside.Translational neurodegeneration · 2025
    Review
  10. Review
  11. Review
  12. Intranasal administration of mesenchymal stem cells overexpressing FGF21 demonstrates therapeutic potential in experimental Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aliaksandr BoikaDepartment of Neurology and Neurosurgery, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus.
Natallia AleinikavaDepartment of Neurology and Neurosurgery, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus.
Veranika ChyzhykDepartment of Neurology and Neurosurgery, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus.
Marina ZafranskayaDepartment of Immunology and Biomedical Technology, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus.
Darya NizheharodavaDepartment of Immunology and Biomedical Technology, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus.
Vladimir PonomarevDepartment of Neurology and Neurosurgery, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of patients with Parkinson disease (PD) using autologous mesenchymal stem cells (MSCs) is a promising method to influence the pathogenesis of the disease. The aim of this study was to assess the immediate results of the introduction of MSCs on the effectiveness of motor and nonmotor symptoms in patients with PD.

methodsMSCs were transplanted to 12 patients with PD through intravenous and tandem (intranasal + intravenous) injections. Effectiveness of the therapy was evaluated 1 and 3 months posttransplantation. Neurological examination of the intensity of motor symptoms was carried out in the morning after a 12 or 24 h break in taking antiparkinsonian drugs, then 1 h after they were taken. The intensity of motor symptoms was assessed with the help of Section III of the Unified PD Rating Scale of the International Society for Movement Disorders (UPDRS). The intensity of nonmotor symptoms was assessed with the help of the following scales: Hamilton Depression Rating Scale, the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, Nonmotor Symptoms Scale, and the 39-item Parkinson's Disease Questionnaire.

resultsWe found a statistically significant decrease in the severity of motor and nonmotor symptoms in the study group in the posttransplant period.

conclusionPositive results allow us to consider MSCs transplantation as a disease-modifying therapeutic strategy in PD. However, this method of PD treatment is not a fully understood process, which requires additional studies and a longer follow-up period to monitor the patients' condition posttransplantation.

Indexed as

Mesenchymal stem cellsMotor symptomsNonmotor symptoms

Identifiers

PMID33408914
PMCPMC7771400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.